Autoantibodies against glial antigens in paraneoplastic neurological diseases

Annals of the New York Academy of Sciences

Volumn 1107, Issue , 2007, Pages 104-110

  Tschernatsch, M ^a   Gross, O ^a   Kneifel, N ^a   Krasenbrink, I ^a   Gerriets, T ^a   Kaps, M ^a   Blaes, F ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

AGNA; Antiglial antibody; Autoimmune; CRMP5; Paraneoplastic neurological syndromes

Indexed keywords

ANTIGEN; AUTOANTIBODY; COLLAPSIN RESPONSE MEDIATOR PROTEIN; GLIA CELL ANTIGEN; GLIAL ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNITY; AUTONOMIC NEUROPATHY; CEREBELLUM DEGENERATION; CONFERENCE PAPER; CRANIAL NEUROPATHY; DEMENTIA; HUMAN; LUNG SMALL CELL CANCER; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUROPATHY; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC SYNDROME; THYMOMA; UTERUS SARCOMA; UVEITIS; ANIMAL; ARTICLE; CELL NUCLEUS; GLIA; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIGENS; AUTOANTIBODIES; AUTOIMMUNITY; CELL NUCLEUS; HUMANS; NEUROGLIA; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 34648823772     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1381.011     Document Type: Conference Paper

References (25)

1. HENSON, R.A. & H. URICH. 1979. Peripheral neuropathy associated with malignant disease. In Handbook of Clinical Neurology. P.J. Vinken, G.W. Bruyn, Eds.: 8: 131-148. Elsevier. Amsterdam.
2. DALMAU, J. & J.B. POSNER. 1997. Paraneoplastic syndromes affecting the nervous system. Semin. Oncol. 24: 318-328.
3. GRAUS, F., J.Y. DELATTRE, J.C. ANTOINE, et al. 2004. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry 75: 1135-1140.
4. WILKINSON, P.C. 1964. Serologic findings in carcinomatous neuromyopathy. Lancet 1: 1301-1303.
5. DALMAU, J., F. GRAUS, M.K. ROSENBLUM, et al. 1992. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71: 59-72.
6. JAECKLE, K.A., F. GRAUS, A. HOUGHTON, et al. 1985. Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmatic protein antigen. Ann. Neurol. 18: 592-600.
7. DALMAU, J., S.H. GULTEKIN, R. VOLTZ, et al. 1999. Ma-1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122: 27-39.
8. VOLTZ, R., S.H. GULTEKIN, M.R. ROSENFELD, et al. 1999. A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N. Engl. J. Med. 340: 1788-1795.
9. VERSCHUUREN, J., J. DALMAU, R. HOARD, et al. 1997. Paraneoplastic anti-Hu serum: studies on human tumor cell lines. J. Neuroimmunol. 79: 202-210.
10. SCHAEFER, K.H., M. KLOTZ, D. MERGNER, et al. 2000. IgG-mediated cytotoxicity to myenteric plexus cultures in patients with paraneoplastic neurological syndromes. J. Autoimmun. 15: 479-484.
11. GREENLEE, J.E., T.N. PARKS & K.A. JAECKLE. 1993. Type IIa (anti-Hu) antineuronal antibodies produce destruction of rat cerebellar granule neurones in vitro. Neurology 43: 2049-2054.
12. GRAUS, F., I. ILLA, M. AGUSTI, et al. 1991. Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model. J. Neurol. Sci. 106: 82-87.
13. TANAKA, M., K. TANAKA, O. ONODERA, et al. 1995. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo-protein, but do not cause Purkinje cell loss. Clin. Neurol. Neurosurg. 97: 95-100.
14. ALBERT, M.L., J.C. DARNELL, A. BENDER, et al. 1998. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4: 1321-1324.
15. BENYAHIA, B., R. LIEBLAU, H. MERLE-BÉRAL, et al. 1999. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann. Neurol. 45: 162-167.
16. PELLKOFER, H., A.S. SCHUBART, R. HOFTBERGER, et al. 2004. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 127: 1822-1830.
17. SHAMS'ILI, S., J. DE BEUKELAAR, J.W. GRATAMA, et al. 2006. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J. Neurol. 253: 16-20.
18. BOGGS, J.M. 2006. Myelin basic protein: a multifunctional protein. Cell. Mol. Life Sci. 63: 1945-1961.
19. REINDL, M., M. KHALIL & T. BERGER. 2006. Antibodies as biological markers for pathophysiological processes in MS. J. Neuroimmunol. 180: 50-62.
20. BAUMANN, N., M.L. HARPIN, Y. MARIE, et al. 1998. Antiglycolipid antibodies in motor neuropathies. Ann. N.Y. Acad. Sci. 845: 322-329.
21. HONNORAT, J., J.C. ANTOINE, E. DERRINGTON, et al. 1996. Antibodies to a subpopulation of glial cells and a 66 kDa developmental protein in patients with paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Pychiatry 61: 270-278.
22. YU, Z., T. J. KRYZER, G.E. GRIESMANN, et al. 2001. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann. Neurol. 49: 146-154.
23. BATALLER, L. & J. DALMAU. 2004. Neuro-ophthalmology and paraneoplastic syndromes. Curr. Opin. Neurol. 17: 3-8.
24. GRAUS, F. & A. VINCENT, P. POZO- ROSICH, et al. 2005. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J. Neuroimmun. 165: 166-171.
25. YAMADA, K. & W. MASAHIKO. 2002. Cytodifferentiation of Bergmann glia and its relationship with Purkinje cells. Anat. Sci. Int. 77: 94-108.